A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e522a2cf-385d-4ca9-8c98-266c71f43a8d
VANCOUVER, British Columbia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC(BABY) (BABYF) (0YL.F) ("Else" or the "Company") the Plant-Based baby, toddler and children nutrition company, is pleased to announce that Dr. Bo Lönnerdal has joined its Scientific Advisory Board.
Dr. Lönnerdal is the Distinguished Professor Emeritus of Nutrition & Internal Medicine at University of California, Davis (UCD). He has an active research program in pediatric nutrition at UCD. He has mentored many undergraduate and graduate students, as well as post-doctoral scholars and visiting scientists from across the world. Dr. Lönnerdal received his master’s and doctorate degrees in biochemistry from the University of Uppsala in Sweden and has been professor at University of California Davis since 1980. Dr. Lönnerdal's research program is focused on two main areas: Infant/Pediatric Nutrition and Trace Element Metabolism.
"We are very pleased that Dr. Lönnerdal has joined our Advisory Board. He’s a world class expert in infant/pediatric nutrition, and his expertise will greatly benefit the Company as we change the paradigm of infant nutrition,” said Hamutal Yitzhak, Else Nutrition CEO & Co-Founder.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The Company recently received the World Plant-Based Award for “Best dairy alternative product” in New York at World Plant-Based Expo in late 2021. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
Investor Relations Contact:
Lytham Partners, LLC
Mr. Ben Shamsian
New York | Phoenix
E: shamsian@lythampartners.com
P: 646-829-9701
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
